Molecular Partners Ag (MOLN) EBITDA Margin Growth (1y) (2021 - 2024)
Powered by 
Analysis
Molecular Partners Ag (MOLN) EBITDA Margin Growth (1y) (2021 - 2024) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 602.00 |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -16,814.00 |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | -143.00 |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 78.00 |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 1,135.00 |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 7,666.00 |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 2,002.00 |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | -2,881.00 |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -1.23 Mn |
| 10 | Molecular Partners Ag | 156.54 Mn | 156.54 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2024 | 209,451.00 |
| Sep 30, 2024 | -161,144.00 |
| Jun 30, 2024 | 279,718.00 |
| Mar 31, 2024 | -8,449.00 |
| Dec 31, 2023 | -92,986.00 |
| Sep 30, 2023 | 9,064.00 |
| Jun 30, 2023 | -377,371.00 |
| Mar 31, 2023 | -58,298.00 |
| Dec 31, 2022 | 71,171.00 |
| Sep 30, 2022 | -25,814.00 |
| Jun 30, 2022 | 73,394.00 |
| Mar 31, 2022 | 198,491.00 |
| Dec 31, 2021 | -2,508.00 |
| Sep 30, 2021 | -572,412.00 |